• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺病毒介导的人血管内皮生长因子可溶性受体(s-VEGFR1)在泪腺中预防角膜新生血管形成。

Prevention of Corneal Neovascularization by Adenovirus Encoding Human Vascular Endothelial Growth Factor Soluble Receptor (s-VEGFR1) in Lacrimal Gland.

机构信息

Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Brazil.

出版信息

Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):6036-6044. doi: 10.1167/iovs.17-22322.

DOI:10.1167/iovs.17-22322
PMID:30574658
Abstract

PURPOSE

The aims of this study were (1) to determine the efficacy of adenovirus vector serotype 5 (Ad) encoding human soluble VEGF receptor 1 (s-VEGFR1) gene transfer to the lacrimal gland (LG); (2) to investigate whether expression of s-VEGFR1 prevents corneal neovascularization (CNV) induced by alkali burns; and (3) to evaluate the safety of the procedure.

METHODS

AdVEGFR1 vectors (25 μL, 1 × 1010 pfu/mL) were injected in the right LGs of rats and were compared with AdNull vector (25 μL, 1 × 1010 pfu/mL) or 25 μL of saline (Control) before cornea alkali burns with 1 M NaOH. After 7 days, CNV was documented at the slit lamp. Tear secretion was measured with phenol red threads. The animals were tested for s-VEGFR1 mRNA and protein in the LG by quantitative (q)PCR and immunohistochemistry staining, respectively. qPCR was used to compare the mRNA levels of IL-1β, IL-6, and TNF-α in the LG and ipsilateral trigeminal ganglion (TG).

RESULTS

Ad-VEGFR1 transfected 83% (10/12) of the rats. VEGFR1 was present in LG acinar cells. CNV was prevented in 9 of 12 animals in the Ad-VEGFR1 group, compared with the Ad-Null (3:10) and Control groups (1:10) (P = 0.0317). The tear secretion and cytokine mRNA levels in the LG and TG were similar in all three groups (P > 0.05).

CONCLUSIONS

Adenoviral vector gene transfer was safe for LG structure and function. The LG as the target tissue showed local expression of human s-VEGFR1, and CNV was prevented in most of the eyes exposed to alkali burns.

摘要

目的

本研究旨在:(1)确定腺病毒载体 5 型(Ad)转染人可溶性血管内皮生长因子受体 1(s-VEGFR1)基因至泪腺(LG)的疗效;(2)探讨 s-VEGFR1 的表达是否能预防碱烧伤诱导的角膜新生血管化(CNV);以及(3)评估该程序的安全性。

方法

AdVEGFR1 载体(25 μL,1×1010 pfu/mL)注入大鼠右侧 LG,与 AdNull 载体(25 μL,1×1010 pfu/mL)或生理盐水(对照组,25 μL)进行比较,之后在角膜上用 1 M NaOH 烧伤。伤后 7 天,裂隙灯观察 CNV。用苯酚红丝测量泪液分泌。通过定量(q)PCR 和免疫组化染色分别检测 LG 中 s-VEGFR1 mRNA 和蛋白。qPCR 用于比较 LG 和同侧三叉神经节(TG)中 IL-1β、IL-6 和 TNF-α的 mRNA 水平。

结果

Ad-VEGFR1 转染了 12 只大鼠中的 10 只(83%)。VEGFR1 存在于 LG 腺泡细胞中。与 Ad-Null(3:10)和对照组(1:10)相比,Ad-VEGFR1 组 12 只动物中有 9 只(9/12)预防了 CNV(P=0.0317)。三组大鼠的 LG 和 TG 的泪液分泌和细胞因子 mRNA 水平均无差异(P>0.05)。

结论

腺病毒载体基因转移对 LG 结构和功能是安全的。LG 作为靶组织,局部表达人 s-VEGFR1,大多数暴露于碱烧伤的眼睛均预防了 CNV。

相似文献

1
Prevention of Corneal Neovascularization by Adenovirus Encoding Human Vascular Endothelial Growth Factor Soluble Receptor (s-VEGFR1) in Lacrimal Gland.腺病毒介导的人血管内皮生长因子可溶性受体(s-VEGFR1)在泪腺中预防角膜新生血管形成。
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):6036-6044. doi: 10.1167/iovs.17-22322.
2
Inhibition of mouse alkali burn induced-corneal neovascularization by recombinant adenovirus encoding human vasohibin-1.编码人血管抑制素-1的重组腺病毒对小鼠碱烧伤诱导的角膜新生血管形成的抑制作用
Mol Vis. 2010 Jul 26;16:1389-98.
3
Lacrimal Gland as a Target Organ for Adenovirus Gene Therapy Encoding Erythropoietin for Dry Eye Induced by Benzalkonium Chloride.将编码促红细胞生成素的腺病毒基因疗法用于治疗苯扎氯铵诱导的干眼症时泪腺作为靶器官的研究
Curr Eye Res. 2021 Sep;46(9):1314-1319. doi: 10.1080/02713683.2021.1893754. Epub 2021 Mar 30.
4
The effect of TC14012 on alkali burn-induced corneal neovascularization in mice.TC14012 对小鼠碱烧伤诱导的角膜新生血管的作用。
Ophthalmic Res. 2014;52(1):17-24. doi: 10.1159/000358201. Epub 2014 May 14.
5
Protective roles of the TIR/BB-loop mimetic AS-1 in alkali-induced corneal neovascularization by inhibiting ERK phosphorylation.TIR/BB 环模拟物 AS-1 通过抑制 ERK 磷酸化在碱诱导的角膜新生血管化中的保护作用。
Exp Eye Res. 2021 Jun;207:108568. doi: 10.1016/j.exer.2021.108568. Epub 2021 Apr 9.
6
Inhibitory effects of gene silencing on alkali burn-induced corneal neovascularization: an in vivo study.基因沉默对碱烧伤诱导的角膜新生血管形成的抑制作用:一项体内研究。
Mol Vis. 2017 Apr 26;23:286-295. eCollection 2017.
7
Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.多西环素增强贝伐单抗对角膜新生血管的抑制作用,并预防其副作用。
Invest Ophthalmol Vis Sci. 2011 Nov 25;52(12):9108-15. doi: 10.1167/iovs.11-7255.
8
Protective Effect of TLR4 Ablation against Corneal Neovascularization following Chemical Burn in a Mouse Model.TLR4 基因敲除对小鼠化学性烧伤后角膜新生血管的保护作用。
Curr Eye Res. 2019 May;44(5):505-513. doi: 10.1080/02713683.2018.1564833. Epub 2019 Jan 24.
9
KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization.KH902,一种重组人 VEGF 受体融合蛋白,降低了碱烧伤诱导的角膜新生血管中胎盘生长因子的水平。
Ophthalmic Res. 2013;50(3):180-6. doi: 10.1159/000353437. Epub 2013 Sep 4.
10
Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury-induced corneal neovascularization.Flt-1细胞内抗体诱导未折叠蛋白反应、凋亡因子并促使小鼠损伤诱导的角膜新生血管消退。
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4787-93. doi: 10.1167/iovs.06-0419.

引用本文的文献

1
VEGFR1 as a Target for Cardiovascular Gene Therapy.血管内皮生长因子受体1作为心血管基因治疗的靶点
J Cardiovasc Transl Res. 2025 Aug 21. doi: 10.1007/s12265-025-10672-5.
2
RIPK3-Mediated Necroptosis Drives Macrophage Infiltration and Corneal Neovascularization After Alkali Burn.RIPK3介导的坏死性凋亡驱动碱烧伤后巨噬细胞浸润和角膜新生血管形成。
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):54. doi: 10.1167/iovs.66.6.54.
3
Forkhead Domain Inhibitor-6 Suppresses Corneal Neovascularization and Subsequent Fibrosis After Alkali Burn in Rats.
叉头框蛋白抑制剂-6 抑制大鼠碱烧伤后角膜新生血管形成及随后的纤维化。
Invest Ophthalmol Vis Sci. 2022 Apr 1;63(4):14. doi: 10.1167/iovs.63.4.14.
4
Limitations and advances in new treatments and future perspectives of corneal blindness.角膜盲的新疗法的局限性和进展及未来展望。
Arq Bras Oftalmol. 2021 May-Jun;84(3):282-296. doi: 10.5935/0004-2749.20210042.
5
Corneal angiogenic privilege and its failure.角膜血管生成特权及其失败。
Exp Eye Res. 2021 Mar;204:108457. doi: 10.1016/j.exer.2021.108457. Epub 2021 Jan 22.
6
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo.SKLB1002,一种有效的 VEGF 受体 2 信号抑制剂,在体外抑制内皮细胞的血管生成功能,在体内抑制眼血管生成。
Mol Med Rep. 2020 Jun;21(6):2571-2579. doi: 10.3892/mmr.2020.11056. Epub 2020 Apr 6.
7
Progress in Research on the Role of FGF in the Formation and Treatment of Corneal Neovascularization.成纤维细胞生长因子在角膜新生血管形成与治疗中作用的研究进展
Front Pharmacol. 2020 Feb 25;11:111. doi: 10.3389/fphar.2020.00111. eCollection 2020.
8
Role of VEGFs/VEGFR-1 Signaling and its Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic Cancer Models.VEGFs/VEGFR-1 信号通路在调节肿瘤侵袭中的作用及其抑制作用:不同转移性癌症模型的实验证据。
Int J Mol Sci. 2020 Feb 18;21(4):1388. doi: 10.3390/ijms21041388.